Dendreon (DNDN) Posts Narrower than Expected Q2 Loss; Withdraws PROVENGE Guidance
Tweet Send to a Friend
Get Alerts DNDN Hot Sheet
Price: $4.01 +1.01%
EPS Growth %: +18.6%
Financial Fact:
Cost of revenue: 43.38M
Today's EPS Names:
LBIX, ESEA, ISS, More
EPS Growth %: +18.6%
Financial Fact:
Cost of revenue: 43.38M
Today's EPS Names:
LBIX, ESEA, ISS, More
Trade DNDN Now!
Dendreon Corp (NASDAQ: DNDN) reported Q2 loss of ($0.57), $0.14 better than the analyst estimate of ($0.71). Revenue for the quarter came in at $49.6 million versus the consensus estimate of $58.58 million.
The Company expects to reduce expenses, including workforce reductions, to align with its near-term manufacturing requirements.
"We believe the market potential for PROVENGE is substantial, and the primary issue affecting the dynamics of our launch is the reimbursement knowledge around PROVENGE. We anticipate the positive National Coverage Determination (NCD) and Q-code will have a significant impact on increased physician adoption. However, we believe this will take time, and for the remainder of 2011, the launch trajectory will reflect a more gradual adoption of PROVENGE as physicians gain confidence in this positive reimbursement landscape," said Mitchell Gold, MD, president and CEO. "With the number of infusion sites increasing substantially, our principal objective continues to be ensuring all eligible patients have access to PROVENGE."
Dendreon expects that adoption of the new reimbursement paradigm will take time. Accordingly, Dendreon is withdrawing its previous guidance of $350-400 million in revenue for 2011 and currently expects modest quarter over quarter revenue growth for the remainder of this year.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
The Company expects to reduce expenses, including workforce reductions, to align with its near-term manufacturing requirements.
"We believe the market potential for PROVENGE is substantial, and the primary issue affecting the dynamics of our launch is the reimbursement knowledge around PROVENGE. We anticipate the positive National Coverage Determination (NCD) and Q-code will have a significant impact on increased physician adoption. However, we believe this will take time, and for the remainder of 2011, the launch trajectory will reflect a more gradual adoption of PROVENGE as physicians gain confidence in this positive reimbursement landscape," said Mitchell Gold, MD, president and CEO. "With the number of infusion sites increasing substantially, our principal objective continues to be ensuring all eligible patients have access to PROVENGE."
Dendreon expects that adoption of the new reimbursement paradigm will take time. Accordingly, Dendreon is withdrawing its previous guidance of $350-400 million in revenue for 2011 and currently expects modest quarter over quarter revenue growth for the remainder of this year.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- UPDATE: Applied Materials, Inc. (AMAT) Tops Q2 EPS by 3c, Offers Guidance
- Brady Corp. (BRC) Misses Q3 EPS by 5c; Guides Q4 EPS Below Views
- Donaldson Co., Inc. (DCI) Misses Q3 EPS by 3c; Guides FY13 Below Views
Create E-mail Alert Related Categories
Earnings, Guidance, Hot Guidance, Trading HaltsRelated Entities
Layoffs
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
